Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 43 | 2024 | 21056 | 1.040 |
Why?
|
Research Design | 15 | 2019 | 6209 | 0.950 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2023 | 10383 | 0.880 |
Why?
|
Models, Statistical | 13 | 2019 | 5089 | 0.830 |
Why?
|
Clinical Trials, Phase III as Topic | 11 | 2021 | 878 | 0.820 |
Why?
|
Proportional Hazards Models | 21 | 2022 | 12509 | 0.800 |
Why?
|
Bayes Theorem | 3 | 2023 | 2354 | 0.700 |
Why?
|
Survival Analysis | 12 | 2015 | 10070 | 0.700 |
Why?
|
Neoplasm Recurrence, Local | 19 | 2024 | 9373 | 0.510 |
Why?
|
Receptors, Estrogen | 11 | 2022 | 2242 | 0.510 |
Why?
|
Neoplasms | 24 | 2025 | 22340 | 0.500 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 25 | 2024 | 11868 | 0.490 |
Why?
|
Antineoplastic Agents, Hormonal | 7 | 2021 | 1534 | 0.480 |
Why?
|
Biostatistics | 3 | 2011 | 162 | 0.460 |
Why?
|
Chemotherapy, Adjuvant | 17 | 2021 | 3537 | 0.450 |
Why?
|
Receptor, erbB-2 | 13 | 2024 | 2593 | 0.430 |
Why?
|
Endpoint Determination | 4 | 2010 | 591 | 0.410 |
Why?
|
Sample Size | 4 | 2019 | 845 | 0.390 |
Why?
|
Clinical Trials, Phase II as Topic | 5 | 2023 | 639 | 0.390 |
Why?
|
GRB7 Adaptor Protein | 1 | 2011 | 2 | 0.390 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2012 | 122 | 0.380 |
Why?
|
Disease-Free Survival | 16 | 2019 | 6832 | 0.370 |
Why?
|
National Cancer Institute (U.S.) | 9 | 2024 | 299 | 0.370 |
Why?
|
Antineoplastic Agents | 13 | 2024 | 13648 | 0.360 |
Why?
|
Doxorubicin | 6 | 2012 | 2230 | 0.350 |
Why?
|
Likelihood Functions | 4 | 2016 | 993 | 0.310 |
Why?
|
Survival Rate | 13 | 2020 | 12795 | 0.300 |
Why?
|
Clinical Trials as Topic | 9 | 2018 | 8041 | 0.290 |
Why?
|
Kaplan-Meier Estimate | 12 | 2021 | 6499 | 0.290 |
Why?
|
Data Interpretation, Statistical | 6 | 2013 | 2686 | 0.280 |
Why?
|
Gene Amplification | 3 | 2025 | 1091 | 0.270 |
Why?
|
Efficiency | 1 | 2010 | 480 | 0.270 |
Why?
|
Professional Staff Committees | 1 | 2006 | 37 | 0.260 |
Why?
|
Tamoxifen | 8 | 2020 | 963 | 0.260 |
Why?
|
Paclitaxel | 6 | 2013 | 1728 | 0.250 |
Why?
|
Patient Dropouts | 1 | 2008 | 410 | 0.250 |
Why?
|
Cluster Analysis | 2 | 2003 | 2721 | 0.250 |
Why?
|
Models, Theoretical | 2 | 2018 | 3564 | 0.230 |
Why?
|
Humans | 107 | 2025 | 765968 | 0.230 |
Why?
|
Receptors, Progesterone | 7 | 2018 | 1153 | 0.230 |
Why?
|
Antigens, Neoplasm | 1 | 2012 | 2002 | 0.230 |
Why?
|
Piperazines | 3 | 2025 | 2549 | 0.220 |
Why?
|
Pyrimidinones | 3 | 2023 | 384 | 0.220 |
Why?
|
Neurofibromin 2 | 1 | 2024 | 268 | 0.210 |
Why?
|
Gene Expression Profiling | 6 | 2020 | 9525 | 0.210 |
Why?
|
Quinazolines | 3 | 2022 | 1364 | 0.200 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 1434 | 0.200 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 4 | 2015 | 920 | 0.200 |
Why?
|
Acrylamides | 1 | 2024 | 257 | 0.200 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2022 | 4044 | 0.190 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2025 | 352 | 0.190 |
Why?
|
Allostasis | 1 | 2022 | 76 | 0.180 |
Why?
|
Lung Neoplasms | 11 | 2024 | 13451 | 0.180 |
Why?
|
Cyclophosphamide | 7 | 2020 | 2228 | 0.180 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2025 | 561 | 0.180 |
Why?
|
Pyridones | 3 | 2023 | 816 | 0.180 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 1106 | 0.180 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2024 | 5389 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2024 | 723 | 0.180 |
Why?
|
Ameloblastoma | 1 | 2021 | 42 | 0.180 |
Why?
|
Female | 63 | 2025 | 396112 | 0.180 |
Why?
|
Cause of Death | 1 | 2011 | 3708 | 0.180 |
Why?
|
Aged | 43 | 2025 | 171117 | 0.180 |
Why?
|
Jaw Neoplasms | 1 | 2021 | 71 | 0.170 |
Why?
|
Mutation | 7 | 2024 | 30198 | 0.170 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2020 | 2054 | 0.170 |
Why?
|
Middle Aged | 49 | 2025 | 223009 | 0.170 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2024 | 341 | 0.170 |
Why?
|
Codon | 1 | 2021 | 595 | 0.160 |
Why?
|
Neoplasms, Second Primary | 2 | 2023 | 1050 | 0.160 |
Why?
|
Benzamides | 2 | 2024 | 1377 | 0.150 |
Why?
|
Aniline Compounds | 1 | 2024 | 1075 | 0.150 |
Why?
|
Transcription, Genetic | 1 | 2012 | 7599 | 0.150 |
Why?
|
Comorbidity | 2 | 2021 | 10563 | 0.150 |
Why?
|
Protein Kinase Inhibitors | 3 | 2025 | 5696 | 0.150 |
Why?
|
Neurofibromatosis 1 | 1 | 2023 | 560 | 0.150 |
Why?
|
Regression Analysis | 3 | 2000 | 6322 | 0.150 |
Why?
|
Medical Oncology | 6 | 2023 | 2339 | 0.140 |
Why?
|
Neutropenia | 1 | 2023 | 893 | 0.140 |
Why?
|
Prognosis | 16 | 2024 | 29922 | 0.140 |
Why?
|
Biometry | 3 | 2011 | 571 | 0.140 |
Why?
|
Antibodies, Monoclonal | 6 | 2011 | 9249 | 0.140 |
Why?
|
GTP Phosphohydrolases | 1 | 2021 | 523 | 0.140 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 248 | 0.140 |
Why?
|
Adult | 41 | 2025 | 223044 | 0.140 |
Why?
|
Computer Simulation | 5 | 2010 | 6255 | 0.140 |
Why?
|
Head and Neck Neoplasms | 1 | 2011 | 2921 | 0.140 |
Why?
|
Pyrimidines | 3 | 2024 | 3047 | 0.130 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2023 | 3655 | 0.130 |
Why?
|
Aged, 80 and over | 18 | 2025 | 59489 | 0.130 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2012 | 3646 | 0.130 |
Why?
|
Algorithms | 7 | 2019 | 14071 | 0.130 |
Why?
|
Indoles | 1 | 2024 | 1839 | 0.130 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 2878 | 0.120 |
Why?
|
Benzimidazoles | 1 | 2021 | 864 | 0.120 |
Why?
|
Insurance Coverage | 3 | 2022 | 1944 | 0.120 |
Why?
|
Mastectomy, Segmental | 3 | 2015 | 964 | 0.120 |
Why?
|
Dissection | 1 | 2016 | 299 | 0.120 |
Why?
|
DNA-Binding Proteins | 1 | 2012 | 9601 | 0.120 |
Why?
|
Mortality | 1 | 2006 | 2904 | 0.120 |
Why?
|
Vincristine | 2 | 2012 | 1039 | 0.110 |
Why?
|
Rare Diseases | 1 | 2019 | 635 | 0.110 |
Why?
|
Bone Plates | 1 | 2016 | 469 | 0.110 |
Why?
|
Premenopause | 3 | 2019 | 1037 | 0.110 |
Why?
|
Linear Models | 1 | 2003 | 5876 | 0.100 |
Why?
|
Treatment Outcome | 16 | 2025 | 65188 | 0.100 |
Why?
|
Tendons | 1 | 2016 | 555 | 0.100 |
Why?
|
Cohort Studies | 3 | 2018 | 41649 | 0.100 |
Why?
|
Medical Audit | 1 | 2013 | 452 | 0.100 |
Why?
|
Self Report | 1 | 2023 | 3770 | 0.100 |
Why?
|
Orgasm | 1 | 2011 | 63 | 0.090 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2020 | 1608 | 0.090 |
Why?
|
False Positive Reactions | 1 | 2013 | 955 | 0.090 |
Why?
|
Colorectal Neoplasms | 3 | 2021 | 6942 | 0.090 |
Why?
|
Multicenter Studies as Topic | 2 | 2008 | 1731 | 0.090 |
Why?
|
Angiogenesis Inhibitors | 2 | 2014 | 2056 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2013 | 3513 | 0.090 |
Why?
|
Radius Fractures | 1 | 2016 | 516 | 0.090 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 83 | 0.090 |
Why?
|
Confidence Intervals | 2 | 2021 | 2910 | 0.090 |
Why?
|
Lymphoma | 1 | 2020 | 1897 | 0.090 |
Why?
|
Probability | 3 | 2008 | 2475 | 0.080 |
Why?
|
United States | 12 | 2024 | 72903 | 0.080 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2010 | 117 | 0.080 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2018 | 1776 | 0.080 |
Why?
|
Fracture Fixation, Internal | 1 | 2016 | 982 | 0.080 |
Why?
|
Neoplasm Staging | 9 | 2019 | 11206 | 0.080 |
Why?
|
Biopsy | 3 | 2020 | 6763 | 0.080 |
Why?
|
Pyrazoles | 1 | 2020 | 2033 | 0.080 |
Why?
|
Combined Modality Therapy | 7 | 2023 | 8529 | 0.080 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 691 | 0.080 |
Why?
|
Melanoma | 2 | 2023 | 5719 | 0.080 |
Why?
|
Patient Compliance | 1 | 2019 | 2692 | 0.080 |
Why?
|
Nevirapine | 1 | 2010 | 273 | 0.080 |
Why?
|
Epidemiologic Measurements | 1 | 2008 | 23 | 0.080 |
Why?
|
Prednisone | 1 | 2012 | 1565 | 0.070 |
Why?
|
Residence Characteristics | 3 | 2022 | 2116 | 0.070 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2022 | 904 | 0.070 |
Why?
|
Interferon-alpha | 2 | 2009 | 910 | 0.070 |
Why?
|
Genomics | 2 | 2023 | 5929 | 0.070 |
Why?
|
Anthracyclines | 2 | 2020 | 284 | 0.070 |
Why?
|
Prospective Studies | 12 | 2021 | 54802 | 0.070 |
Why?
|
Risk Assessment | 5 | 2019 | 24282 | 0.070 |
Why?
|
Predictive Value of Tests | 4 | 2019 | 15398 | 0.060 |
Why?
|
Taxoids | 2 | 2020 | 665 | 0.060 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2008 | 594 | 0.060 |
Why?
|
E-Selectin | 1 | 2008 | 576 | 0.060 |
Why?
|
Lymph Node Excision | 1 | 2011 | 1259 | 0.060 |
Why?
|
Carboplatin | 4 | 2011 | 789 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2012 | 14652 | 0.060 |
Why?
|
Adenocarcinoma | 3 | 2012 | 6364 | 0.060 |
Why?
|
Imidazoles | 2 | 2022 | 1162 | 0.060 |
Why?
|
Young Adult | 9 | 2024 | 59889 | 0.060 |
Why?
|
Disease Progression | 5 | 2020 | 13632 | 0.060 |
Why?
|
Robotics | 1 | 2011 | 809 | 0.060 |
Why?
|
Recurrence | 3 | 2012 | 8501 | 0.060 |
Why?
|
Male | 20 | 2025 | 363698 | 0.060 |
Why?
|
Risk Factors | 7 | 2024 | 74840 | 0.060 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2008 | 1132 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2022 | 5197 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2021 | 7851 | 0.060 |
Why?
|
Membrane Glycoproteins | 1 | 2014 | 3690 | 0.050 |
Why?
|
Fluorouracil | 3 | 2020 | 1648 | 0.050 |
Why?
|
Prostatectomy | 1 | 2011 | 1782 | 0.050 |
Why?
|
Postmenopause | 2 | 2010 | 2515 | 0.050 |
Why?
|
Statistics, Nonparametric | 1 | 2008 | 2844 | 0.050 |
Why?
|
Lymphatic Metastasis | 5 | 2011 | 2887 | 0.050 |
Why?
|
Gene Expression | 2 | 2015 | 7584 | 0.050 |
Why?
|
Double-Blind Method | 3 | 2013 | 12437 | 0.050 |
Why?
|
Analysis of Variance | 3 | 2000 | 6203 | 0.050 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2023 | 103 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2014 | 16047 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2022 | 2505 | 0.050 |
Why?
|
Ovariectomy | 1 | 2004 | 611 | 0.050 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2023 | 150 | 0.050 |
Why?
|
Pyridines | 2 | 2025 | 2888 | 0.050 |
Why?
|
Oxazepines | 1 | 2022 | 22 | 0.050 |
Why?
|
Neoplasm Invasiveness | 3 | 2018 | 3602 | 0.050 |
Why?
|
Advisory Committees | 1 | 2006 | 796 | 0.050 |
Why?
|
Nerve Tissue Proteins | 1 | 2014 | 4392 | 0.050 |
Why?
|
Cyclin D1 | 1 | 2023 | 449 | 0.050 |
Why?
|
Mathematics | 2 | 1994 | 696 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2012 | 3596 | 0.040 |
Why?
|
Methotrexate | 2 | 2020 | 1722 | 0.040 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2020 | 92 | 0.040 |
Why?
|
Follow-Up Studies | 7 | 2018 | 39193 | 0.040 |
Why?
|
Laparoscopy | 1 | 2011 | 2039 | 0.040 |
Why?
|
Time Factors | 6 | 2019 | 40065 | 0.040 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2013 | 1083 | 0.040 |
Why?
|
Stroke | 1 | 2021 | 9747 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2009 | 3222 | 0.040 |
Why?
|
Pyrazines | 1 | 2024 | 1204 | 0.040 |
Why?
|
Oximes | 1 | 2020 | 305 | 0.040 |
Why?
|
Estrogen Antagonists | 1 | 2019 | 150 | 0.040 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2020 | 330 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2019 | 9071 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2009 | 5786 | 0.040 |
Why?
|
Thiotepa | 2 | 2010 | 66 | 0.040 |
Why?
|
RNA, Messenger | 1 | 2012 | 12768 | 0.030 |
Why?
|
Estrogen Receptor alpha | 1 | 2021 | 578 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2015 | 12056 | 0.030 |
Why?
|
Age Factors | 3 | 2019 | 18380 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2019 | 790 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2013 | 8611 | 0.030 |
Why?
|
Aromatase Inhibitors | 1 | 2020 | 518 | 0.030 |
Why?
|
Neoplasm Metastasis | 3 | 2013 | 4893 | 0.030 |
Why?
|
Diarrhea | 1 | 2022 | 1316 | 0.030 |
Why?
|
Carcinoma, Lobular | 2 | 2011 | 471 | 0.030 |
Why?
|
Sulfonamides | 1 | 2024 | 1984 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2014 | 20124 | 0.030 |
Why?
|
Pyrroles | 1 | 2021 | 1119 | 0.030 |
Why?
|
Software | 1 | 2008 | 4462 | 0.030 |
Why?
|
Altretamine | 1 | 1994 | 11 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5337 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1549 | 0.030 |
Why?
|
Hypertension | 1 | 2014 | 8626 | 0.030 |
Why?
|
Genetic Variation | 1 | 2009 | 6610 | 0.030 |
Why?
|
Treatment Failure | 1 | 2000 | 2652 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2004 | 2631 | 0.030 |
Why?
|
Erythropoietin | 1 | 1997 | 716 | 0.030 |
Why?
|
Social Class | 1 | 2022 | 2007 | 0.030 |
Why?
|
Epidemiologic Methods | 1 | 1998 | 1326 | 0.030 |
Why?
|
Menopause | 1 | 2021 | 1659 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2000 | 1376 | 0.030 |
Why?
|
Retrospective Studies | 7 | 2021 | 81514 | 0.030 |
Why?
|
Etoposide | 1 | 1994 | 636 | 0.020 |
Why?
|
Patient Selection | 2 | 2016 | 4255 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2021 | 2453 | 0.020 |
Why?
|
Therapeutic Equipoise | 1 | 2011 | 29 | 0.020 |
Why?
|
Carcinoma, Small Cell | 1 | 1994 | 420 | 0.020 |
Why?
|
Trauma, Nervous System | 1 | 2011 | 35 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2013 | 545 | 0.020 |
Why?
|
Fenretinide | 1 | 2010 | 9 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2021 | 2880 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2008 | 22223 | 0.020 |
Why?
|
Night Blindness | 1 | 2010 | 58 | 0.020 |
Why?
|
Incidence | 1 | 2008 | 21480 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2009 | 5849 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2022 | 5526 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2022 | 3928 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2822 | 0.020 |
Why?
|
Axilla | 1 | 2011 | 615 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2011 | 11083 | 0.020 |
Why?
|
Coronary Artery Bypass | 1 | 1997 | 2186 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4562 | 0.020 |
Why?
|
Stroke Volume | 1 | 2022 | 5596 | 0.020 |
Why?
|
Infant | 1 | 2010 | 36386 | 0.020 |
Why?
|
Erectile Dysfunction | 1 | 2011 | 437 | 0.020 |
Why?
|
Lymph Nodes | 2 | 2010 | 3454 | 0.020 |
Why?
|
Carcinoma, Large Cell | 1 | 2008 | 114 | 0.020 |
Why?
|
Reference Values | 1 | 1994 | 4908 | 0.020 |
Why?
|
Mastectomy | 1 | 2015 | 1847 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2021 | 5783 | 0.020 |
Why?
|
Time | 1 | 2008 | 550 | 0.020 |
Why?
|
Brain Mapping | 1 | 2021 | 6601 | 0.020 |
Why?
|
Recombinant Proteins | 2 | 2009 | 6493 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2003 | 5753 | 0.010 |
Why?
|
Medicare | 1 | 2022 | 6823 | 0.010 |
Why?
|
HIV Infections | 1 | 2010 | 17533 | 0.010 |
Why?
|
Patient Participation | 1 | 2011 | 1455 | 0.010 |
Why?
|
Data Collection | 1 | 2011 | 3318 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2015 | 11022 | 0.010 |
Why?
|
Cell Division | 1 | 2009 | 4475 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2009 | 4850 | 0.010 |
Why?
|
Recovery of Function | 1 | 2011 | 2966 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 13024 | 0.010 |
Why?
|
Random Allocation | 1 | 2004 | 2395 | 0.010 |
Why?
|
Internet | 1 | 2011 | 3106 | 0.010 |
Why?
|
Blood Pressure | 1 | 2014 | 8532 | 0.010 |
Why?
|
Thalidomide | 1 | 2004 | 886 | 0.010 |
Why?
|
Survivors | 1 | 2009 | 2372 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 2003 | 2120 | 0.010 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2001 | 409 | 0.010 |
Why?
|
Epoetin Alfa | 1 | 1997 | 78 | 0.010 |
Why?
|
Amenorrhea | 1 | 2001 | 470 | 0.010 |
Why?
|
Sex Factors | 1 | 2011 | 10603 | 0.010 |
Why?
|
Risk | 1 | 2008 | 9591 | 0.010 |
Why?
|
Hematocrit | 1 | 1997 | 621 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2014 | 12807 | 0.010 |
Why?
|
Child | 1 | 2023 | 80564 | 0.010 |
Why?
|
Brain | 1 | 2021 | 27171 | 0.010 |
Why?
|
Age of Onset | 1 | 2001 | 3344 | 0.010 |
Why?
|
Adolescent | 1 | 2020 | 88835 | 0.010 |
Why?
|
Hemoglobins | 1 | 1997 | 1530 | 0.010 |
Why?
|
Blood Transfusion | 1 | 1997 | 1297 | 0.010 |
Why?
|
Antibodies | 1 | 1997 | 2417 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2011 | 15747 | 0.000 |
Why?
|
Aging | 1 | 2001 | 8731 | 0.000 |
Why?
|